Antitumor efficacy of 34.5ENVE: A transcriptionally retargeted and vstat120-expressing oncolytic virus

Molecular Therapy

Volumn 20, Issue 2, 2012, Pages 287-297

  Yoo, Ji Young ^a   Haseley, Amy ^a   Bratasz, Anna ^a,b   Chiocca, E Antonio ^a   Zhang, Jianying ^a   Powell, Kimerly ^a,b   Kaur, Balveen ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; GADOLINIUM PENTETATE; ONCOLYTIC VIRUS; PROTEIN VSTAT120; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PARAMETERS; CANCER SURVIVAL; CONTROLLED STUDY; DRUG TARGETING; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; GENE EXPRESSION; GLIOMA; HERPES SIMPLEX VIRUS 1; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACRANIAL TUMOR; MICROVESSEL DENSITY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; SUBCUTANEOUS TISSUE TUMOR; TUMOR MICROENVIRONMENT; TUMOR NECROSIS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL LINE; CELL MOVEMENT; CYTOPATHOGENIC EFFECT, VIRAL; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION; GENE ORDER; GENE THERAPY; GENETIC VECTORS; GLIOMA; HERPESVIRUS 1, HUMAN; HUMANS; INTERMEDIATE FILAMENT PROTEINS; MICE; MICE, NUDE; NECROSIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NERVE TISSUE PROTEINS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SURVIVAL ANALYSIS; VIRUS REPLICATION;

HUMAN HERPESVIRUS 1; MUS;

EID: 84863011273     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.208     Document Type: Article

References (39)

1. Stupp, R, Mason, WP, van den Bent, MJ, Weller, M, Fisher, B, Taphoorn, MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. (Pubitemid 40349501)
2. Markert, JM, Liechty, PG, Wang, W, Gaston, S, Braz, E, Karrasch, M et al. (2009). Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 17: 199-207.
3. Markert, JM, Medlock, MD, Rabkin, SD, Gillespie, GY, Todo, T, Hunter, WD et al. (2000). Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7: 867-874. (Pubitemid 30303584)
4. Post, DE, Khuri, FR, Simons, JW, Van Meir, EG (2003). Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 14: 933-946. (Pubitemid 36829727)
5. Hardcastle, J, Kurozumi, K, Dmitrieva, N, Sayers, MP, Ahmad, S, Waterman, P et al. (2010). Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther 18: 285-294.
6. Prabhakar, S, Messerli, SM, Stemmer-Rachamimov, AO, Liu, TC, Rabkin, S, Martuza, R et al. (2007). Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Cancer Gene Ther 14: 460-467. (Pubitemid 46588196)
7. Hardcastle, J, Kurozumi, K, Chiocca, EA and Kaur, B (2007). Oncolytic viruses driven by tumor-specific promoters. Curr Cancer Drug Targets 7: 181-189. (Pubitemid 46348633)
8. Wojton, J and Kaur, B (2010). Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev 21: 127-134.
9. Kambara, H, Okano, H, Chiocca, EA and Saeki, Y (2005). An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 65: 2832-2839. (Pubitemid 40490086)
10. Kambara, H, Saeki, Y and Chiocca, EA (2005). Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res 65: 11255-11258. (Pubitemid 41821678)
11. Mahller, YY, Williams, JP, Baird, WH, Mitton, B, Grossheim, J, Saeki, Y et al. (2009). Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS ONE 4: e4235.
12. Terada, K, Wakimoto, H, Tyminski, E, Chiocca, EA and Saeki, Y (2006). Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther 13: 705-714.
13. Chou, J, Chen, JJ, Gross, M and Roizman, B (1995). Association of a M 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 and premature shutoff of protein synthesis after infection with gamma 134.5-mutants of herpes simplex virus 1. Proc Natl Acad Sci USA 92: 10516-10520. (Pubitemid 3009119)
14. Weidner, N, Semple, JP, Welch, WR and Folkman, J (1991). Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8.
15. Kerwin, WS, O'Brien, KD, Ferguson, MS, Polissar, N, Hatsukami, TS and Yuan, C (2006). Inflammation in carotid atherosclerotic plaque: a dynamic contrast-enhanced MR imaging study. Radiology 241: 459-468. (Pubitemid 44632892)
16. Egeland, TA, Gaustad, JV, Galappathi, K and Rofstad, EK (2011). Magnetic resonance imaging of tumor necrosis. Acta Oncol 50: 427-434.
17. Friedman, A, Tian, JP, Fulci, G, Chiocca, EA and Wang, J (2006). Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res 66: 2314-2319.
18. Ishiwata, T, Matsuda, Y and Naito, Z (2011). Nestin in gastrointestinal and other cancers: effects on cells and tumor angiogenesis. World J Gastroenterol 17: 409-418.
19. Kaur, B, Cripe, TP and Chiocca, EA (2009). "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther 9: 341-355.
20. Kaur, B, Brat, DJ, Calkins, CC and Van Meir, EG (2003). Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. Am J Pathol 162: 19-27. (Pubitemid 36041986)
21. Nishimori, H, Shiratsuchi, T, Urano, T, Kimura, Y, Kiyono, K, Tatsumi, K et al. (1997). A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene 15: 2145-2150. (Pubitemid 27493903)
22. Fukushima, Y, Oshika, Y, Tsuchida, T, Tokunaga, T, Hatanaka, H, Kijima, H et al. (1998). Brain-specific angiogenesis inhibitor 1 expression is inversely correlated with vascularity and distant metastasis of colorectal cancer. Int J Oncol 13: 967-970. (Pubitemid 28506065)
23. Hatanaka, H, Oshika, Y, Abe, Y, Yoshida, Y, Hashimoto, T, Handa, A et al. (2000). Vascularization is decreased in pulmonary adenocarcinoma expressing brain-specific angiogenesis inhibitor 1 (BAI1). Int J Mol Med 5: 181-183.
24. Lee, JH, Koh, JT, Shin, BA, Ahn, KY, Roh, JH, Kim, YJ et al. (2001). Comparative study of angiostatic and anti-invasive gene expressions as prognostic factors in gastric cancer. Int J Oncol 18: 355-361.
25. Kudo, S, Konda, R, Obara, W, Kudo, D, Tani, K, Nakamura, Y et al. (2007). Inhibition of tumor growth through suppression of angiogenesis by brain-specific angiogenesis inhibitor 1 gene transfer in murine renal cell carcinoma. Oncol Rep 18: 785-791.
26. Kaur, B, Brat, DJ, Devi, NS and Van Meir, EG (2005). Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene 24: 3632-3642. (Pubitemid 40756232)
27. Kaur, B, Cork, SM, Sandberg, EM, Devi, NS, Zhang, Z, Klenotic, PA et al. (2009). Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res 69: 1212-1220.
28. Klenotic, PA, Huang, P, Palomo, J, Kaur, B, Van Meir, EG, Vogelbaum, MA et al. (2010). Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin. Am J Pathol 176: 2039-2050.
29. Koh, JT, Kook, H, Kee, HJ, Seo, YW, Jeong, BC, Lee, JH et al. (2004). Extracellular fragment of brain-specific angiogenesis inhibitor 1 suppresses endothelial cell proliferation by blocking ?v?5 integrin. Exp Cell Res 294: 172-184. (Pubitemid 38232664)
30. Kurozumi, K, Hardcastle, J, Thakur, R, Shroll, J, Nowicki, M, Otsuki, A et al. (2008). Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther 16: 1382-1391.
31. Aghi, M, Rabkin, SD and Martuza, RL (2007). Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res 67: 440-444. (Pubitemid 46192178)
32. Kurozumi, K, Hardcastle, J, Thakur, R, Yang, M, Christoforidis, G, Fulci, G et al. (2007). Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 99: 1768-1781. (Pubitemid 351767207)
33. Breitbach, CJ, Paterson, JM, Lemay, CG, Falls, TJ, McGuire, A, Parato, KA et al. (2007). Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 15: 1686-1693. (Pubitemid 47289013)
34. Narita, Y, Nagane, M, Mishima, K, Huang, HJ, Furnari, FB and Cavenee, WK (2002). Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res 62: 6764-6769. (Pubitemid 35364149)
35. Yoo, JY, Kim, JH, Kwon, YG, Kim, EC, Kim, NK, Choi, HJ et al. (2007). VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther 15: 295-302. (Pubitemid 46111879)
36. Choi, WW, Lewis, MM, Lawson, D, Yin-Goen, Q, Birdsong, GG, Cotsonis, GA et al. (2005). Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol 18: 143-152. (Pubitemid 40128107)
37. Yoo, JY, Kim, JH, Kim, J, Huang, JH, Zhang, SN, Kang, YA et al. (2008). Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. Gene Ther 15: 635-651. (Pubitemid 351524518)
38. Haacke, EM, Filleti, CL, Gattu, R, Ciulla, C, Al-Bashir, A, Suryanarayanan, K et al. (2007). New algorithm for quantifying vascular changes in dynamic contrastenhanced MRI independent of absolute T1 values. Magn Reson Med 58: 463-472. (Pubitemid 350154956)
39. Kuo, YT, Herlihy, AH, So, PW, Bhakoo, KK and Bell, JD (2005). In vivo measurements of T1 relaxation times in mouse brain associated with different modes of systemic administration of manganese chloride. J Magn Reson Imaging 21: 334-339. (Pubitemid 40446425)